Hepatitis B and C seroprevalence in patients with diabetes mellitus and its relationship with microvascular complications by Kadir Gisi, Ali Cetinkaya, Mesut Ozkaya, Bulent Kantarceken, Gokce Gisi, Sedat Koroglu

Subjects: Get full text

Sociodemographic and clinical profiles of individuals with opioid dependence syndrome presenting to a tertiary care center in Assam: A retrospective review by Pranjal J. Chakravarty, Tathagata Mahintamani, Diptadhi Mukherjee, Partha P. Daimary, Hemanta Dutta

Subjects: Get full text

Towards an HCV vaccine: an overview of the immunization strategies for eliciting an effective B-cell response by Gabriel L. Costa, Giuseppe A. Sautto

Subjects: “…Hepatitis C virus (HCV)…”
Get full text

Spontaneous splenic rupture associated with Q fever and portal hypertension: A case report by Cecil Mustafiz, Cecil Mustafiz, Deloshaan Subhaharan, Deloshaan Subhaharan, Daniel Chorley, Tariq Masood

Subjects: Get full text

Coinfection of Hepatitis B and C Viruses and Risk of Hepatocellular Carcinoma: Systematic Review and Meta-analysis by Abdullah A. Awadh, Abdulrahman A. Alharthi, Basil A. Alghamdi, Seraj T. Alghamdi, Mohammed K. Baqays, Ibrahim S. Binrabaa, Israa A. Malli

Subjects: Get full text

Prevalence and risk implications of Hepatitis B and C Viruses in a University community in Lagos, Nigeria by Oluwaseyi Ashaka, Chinyere Ezeanya-Bakpa, Fehintiola Olukoya, Caleb Awodesu, Oluwademilade Abdulkadir, Philip Mbata, Faithfulness Yangs, Abimbola Orukotan

Subjects: Get full text

Generalized linear modeling of HCV infection among medical waste handlers in Sidama region, Ethiopia by Birhanu Betela Warssamo

Subjects: “…hepatitis C virus…”
Get full text

Predictors of response to daclatasvir in addition to sofosbuvir in hepatitis C virus-infected patients with stage 4 and 5 chronic kidney disease and patients on maintenance hemodialysis by Rasha Gawish, Eman Elgohary, Mona Tahoun, Mona Elkaraly, Heba Mohsin, Ahmed Kamal

Subjects: “…Hepatitis C…”
Get full text

The impact of genetic polymorphisms of IL28B gene on the efficacy of antiviral therapy of the chronic hepatitis C by using the standard Interferon-<i>α</i> by A. V. Lapshin, M. V. Mayevskaya, V. T. Ivashkin, P. O. Bogomolov, I. G. Nikitin, O. O. Znoyko

Subjects: “…chronic hepatitis c…”
Get full text

Vitamin D Potentiates the Inhibitory Effect of MicroRNA-130a in Hepatitis C Virus Replication Independent of Type I Interferon Signaling Pathway by Xiaoqiong Duan, Yujuan Guan, Yujia Li, Shan Chen, Shilin Li, Limin Chen

Get full text

Theoretical modeling of hepatitis C acute infection in liver-humanized mice support pre-clinical assessment of candidate viruses for controlled-human-infection studies by Zhenzhen Shi, Adquate Mhlanga, Yuji Ishida, Ari Josephson, Nicholson T. Collier, Hiromi Abe-Chayama, Chise Tateno-Mukaidani, Scott J. Cotler, Jonathan Ozik, Marian Major, Jordan J. Feld, Kazuaki Chayama, Harel Dahari

Subjects: “…Hepatitis C virus…”
Get full text

Frekuensi Hepatitis B dan Hepatitis C Positif pada Darah Donor di Unit Transfusi Darah Cabang Padang pada Tahun 2012 by Dewi Oktavia, Rismawati Yaswir, Nora Harminarti

“…Infeksi virus hepatitis B dan hepatitis C akut bisa bergejala (simptomatik) atau tidak bergejala (asimptomatik). …”
Get full text

Serum Activins and Follistatin during the Treatment of Chronic Hepatitis C Genotypes 1 and 4 and Their Correlations with Viral Load and Liver Enzymes: A Preliminary Report by Bassem Refaat, Adel Galal El-Shemi, Ahmed Mohamed Ashshi, Adnan AlZanbagi

“…To measure the effect of pegylated interferon-α therapy on serum activin-A, activin-B, and follistatin and their correlation with viral load and liver fibrosis in chronic hepatitis C (CHC). Methods. This study was cross-sectional and sera were collected from 165 participants classified into 7 groups: 40 healthy negative control, 33 treatment naïve patients as positive control, 19 patients at week 4, 22 at week 12, and 19 at week 24 of treatment initiation and 21 responders and 11 nonresponders at the end of 48-week treatment protocol. …”
Get full text

Evaluation of Oral Cannabinoid-Containing Medications for the Management of Interferon and Ribavirin-Induced Anorexia, Nausea and Weight Loss in Patients Treated for Chronic Hepatitis C Virus by Cecilia T Costiniuk, Edward Mills, Curtis L Cooper

“…OBJECTIVES: The systemic and cognitive side effects of hepatitis C virus (HCV) therapy may be incapacitating, necessitating dose reductions or abandonment of therapy. …”
Get full text

Association between High-Sensitivity C-Reactive Protein and N-Terminal Pro-B-Type Natriuretic Peptide in Patients with Hepatitis C Virus Infection by Wenliang Che, Buchun Zhang, Wenling Liu, Yidong Wei, Yawei Xu, Dayi Hu

Get full text

Hepatitis C Virus and Nonliver Solid Cancers: Is There an Association between HCV and Cancers of the Pancreas, Thyroid, Kidney, Oral Cavity, Breast, Lung, and Gastrointestinal Tract? by Saad Qadwai, Tayyaba Rehman, Jonathan Barsa, Zeeshan Solangi, Edward Lebovics

“…Hepatitis C virus (HCV) is known for its oncogenic potential and has been found to be associated with hepatocellular carcinoma (HCC) and non-Hodgkin lymphoma. …”
Get full text

Interleukin 28B polymorphism impact on early HCV kinetics in HCV-infected liver transplant recipients undergoing antiviral therapy by V. E. Syutkin, V. P. Chulanov, I. V. Karandashova, V. A. Dolgin, A. O. Chugunov

Subjects: Get full text

The combined therapy of chronic hepatitis with pegilated interferon <i>a</i>-2а and ribavirin in patients with HIV-infection and patients with HCV monoinfection by N. D. Yuschuk, S. L. Maximov, L. M. Ivanova, Ye. K. Klimova, O. O. Znoyko, A. V. Kravchenko

Subjects: “…chronic hepatitis c…”
Get full text

Virus-Mimicking Polymer Nanocomplexes Co-Assembling HCV E1E2 and Core Proteins with TLR 7/8 Agonist—Synthesis, Characterization, and In Vivo Activity by Thomas R. Fuerst, Alexander Marin, Sarah Jeong, Liudmila Kulakova, Raman Hlushko, Katrina Gorga, Eric A. Toth, Nevil J. Singh, Alexander K. Andrianov

Subjects: Get full text

Efficacy and safety of the Russian protease inhibitor narlaprevir at treatment-naive and earlier treated noncirrhotic patients with the 1st genotype chronic hepatitis C (PIONEER study) by M. V. Mayevskaya, V. T. Ivashkin, O. O. Znoyko, Ye. A. Klimova, D. T. Abdurakhmanov, I. G. Bakulin, P. O. Bogomolov, E. Z. Burnevich, M. Yu. Galushko, N. I. Geyvandova, K. V. Zhdanov, Ye. V. Esaulenko, S. N. Kizhlo, D. Yu. Konstantinov, N. I. Mironova, V. G. Morozov, Ye. A. Strebkova, I. G. Nikitin, M. F. Osipenko, V. D. Pasechnikov, O. I. Sagalova, I. M. Khayertynova, V. P. Chulanov, A. A. Yakovlev, I. A. Vasyutin, Ye. P. Tarkhova, E. N. Krasavina, M. Yu. Samsonov

“…To estimate efficacy and safety of narlaprevir (NVR) with ritonavir (RTV), pegilated interferon (peg-IFN) and ribavirin (RBV) at treatmentnaïve and earlier treated noncirrhotic patients with chronic hepatitis C caused by the 1st virus genotype in double blind placebo-controlled 3rd phase study (PIONEER). …”
Get full text